Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study

PURPOSE: To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) study. On the basis of observed early clinical activity, we expanded the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Gervais, Radj, Riely, Gregory, Hollebecque, Antoine, Blay, Jean-Yves, Felip, Enriqueta, Schuler, Martin, Gonçalves, Anthony, Italiano, Antonio, Keedy, Vicki, Chau, Ian, Puzanov, Igor, Raje, Noopur S., Meric-Bernstam, Funda, Makrutzki, Martina, Riehl, Todd, Pitcher, Bethany, Baselga, Jose, Hyman, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446432/
https://www.ncbi.nlm.nih.gov/pubmed/32914022
http://dx.doi.org/10.1200/PO.18.00266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446432/
https://www.ncbi.nlm.nih.gov/pubmed/32914022
http://dx.doi.org/10.1200/PO.18.00266

Ejemplares similares